Corticosteroid Use in Hospice and Palliative Care

Introduction to Corticosteroid Selection

The American College of Physicians recommends choosing dexamethasone as the preferred corticosteroid for most hospice and palliative care patients requiring symptom management, using 4-8 mg daily as the standard dose, with prednisone reserved for patients at high risk for neuropsychiatric complications or requiring longer-term therapy exceeding 6 weeks 1

Dexamethasone is preferred when CNS symptoms are present, including brain metastases, increased intracranial pressure, or spinal cord compression, due to superior CNS penetration 2, 1
Prednisone is preferred when a history of psychiatric disorders exists, as dexamethasone carries 4.55 times higher risk of neuropsychiatric adverse events 1
Prednisone is also preferred when longer-term therapy is required, where it demonstrates better tolerability 1, 3

The standard palliative dose of dexamethasone is 4-8 mg daily, with 8 mg divided twice daily being most common among palliative care providers, although the exact dosing may vary 1
The maximum conventional dose of dexamethasone for brain metastases is 16 mg/day for tumor-associated edema 2
The standard dose of prednisone is 1-2 mg/kg/day for acute symptom management 3

Dexamethasone has a risk ratio of 4.55 for neuropsychiatric effects and 7.05 for myopathy compared to prednisone 1
Osteoporosis and fractures are potential adverse effects of long-term corticosteroid use 3
Cushingoid features, such as weight gain, facial changes, and peripheral edema, can occur with corticosteroid use 2

The National Comprehensive Cancer Network recommends avoiding indefinite continuation of corticosteroids and reducing the dose to the lowest effective level as soon as possible, although the exact guidelines may vary 4